Other languages Senti Biosciences, Inc.

Equities

SNTI

US81726A1007

End-of-day quote Nasdaq Other stock markets 03:30:00 01/05/2024 am IST			5-day change	1st Jan Change
0.38 ^USD	+5.56%		+35.28%	-42.42%

30/04	Senti Biosciences, Inc. Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia	CI
26/04	Senti Biosciences, Inc. Announces Resignation of Deborah Knobelman as Chief Financial Officer, Effective May 3, 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Senti Biosciences, Inc. Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia	30/04
Senti Biosciences, Inc. Announces Resignation of Deborah Knobelman as Treasurer and Head of Corporate Development, Effective May 3, 2024	27/04
Senti Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/03
Senti Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	22/03
Spark Therapeutics, Inc. Announces Workforce Reduction	06/01
Top Premarket Gainers	22/12
Senti Biosciences, Inc. Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia	22/12
Senti Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Senti Biosciences, Inc. Announces New Strategic Collaboration with Celest Therapeutics Co. Ltd	07/11
Senti Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11
Senti Biosciences, Inc. Announces Resignation of Philip Lee as Chief Technology Officer	10/23/10
GeneFab, LLC acquired Rights, title and interest in certain of the assets from Senti Biosciences, Inc. for $37.8 million.	10/23/10
Senti Biosciences, Inc. Highlights Initial Gene Circuit Data from Collaborations At the American Society of Gene and Cell Therapy Annual Meeting	20/23/20
Senti Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	10/23/10
Senti Biosciences, Inc. Highlights Preclinical Data from Multiple Gene Circuit Enabled Cell Therapy Programs At Annual American Association for Cancer Research Meeting	17/23/17
Senti Biosciences, Inc. Announces Strategic Plan to Focus Research and Development Efforts on Lead Oncology Candidate SENTI-202	23/23/23
Senti Biosciences, Inc. Auditor Raises 'Going Concern' Doubt	22/23/22
Senti Biosciences, Inc. Announces Three Preclinical Data Presentations from Gene Circuit-Enhanced CAR-NK Cell Oncology Pipeline at Annual AACR Meeting	15/23/15
Senti Biosciences, Inc. Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies	27/23/27
Senti Biosciences, Inc. Highlights Preclinical Data from Logic-Gated Gene Circuit CAR-NK Cell Therapy SENTI-202 at ASH Annual Meeting and Investor Event	11/22/11

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Senti Biosciences, Inc.

Equities

SNTI

US81726A1007

Other languages

Filters